Appetite hormones drift back toward where they were before treatment once a GLP-1 clears your system, and that is the real reason hunger and food noise tend to return after stopping. In the semaglutide withdrawal extension of the STEP 1 trial, participants who switched to placebo after 20 weeks on treatment regained close to two-thirds of their lost weight within the following year, while those who stayed on treatment continued to lose. That is not a willpower story. It is what happens when a hormone signal that was quieting appetite stops being reinforced.

Why appetite comes back

GLP-1 medications work by mimicking a natural gut hormone that signals fullness and slows how quickly your stomach empties, which is a large part of why appetite and food noise both quiet down on treatment. That effect depends on the drug being active in your system. Once you stop, the medication clears out over roughly a week to several weeks depending on which one you were taking, and the appetite-regulating signal it was providing goes with it. Your body's own hunger and fullness hormones do not stay suppressed on their own, they return to functioning the way they did before you started, which is exactly why the hunger and mental chatter about food tend to come back around the same time.

What the trial data shows

The clearest evidence on this comes from randomized withdrawal studies, where researchers deliberately compared people who stayed on treatment against people who were switched to placebo. In the semaglutide extension published in JAMA, the placebo group regained an average of about two-thirds of the weight they had lost by roughly a year after stopping, while continuing weight loss and cardiometabolic improvements were seen in the group that stayed on treatment. That number describes an average across a study population, not a guarantee for any one person, but it is the best evidence available for what tends to happen when the medication itself is removed from the picture.

Why it is not the same for everyone

Averages hide a wide spread. Some people in these trials regained very little, and some regained more than they had originally lost. What separated the two groups in follow-up analysis was less about biology and more about what happened to the habits built during treatment, whether protein intake, movement, and self-monitoring continued or quietly dropped away once the appetite suppression that had been making those habits easier disappeared. That is genuinely useful information, because it means the outcome is not fixed the moment the medication stops.

It also matters how long someone was on treatment before stopping, and how much of that time went toward building habits versus simply relying on reduced appetite to do the work. Someone who used the quieter months to build a consistent protein and movement routine tends to have more in place once appetite returns than someone who mostly coasted on the appetite suppression itself. Neither pattern is a moral failing, but they predictably lead to different outcomes once the medication is no longer doing part of the job.

Does this apply across the whole drug class

Yes, in general shape. Tirzepatide, the compound behind Zepbound and Mounjaro, works on an overlapping set of gut hormone receptors and shows a similar withdrawal pattern in its own trial data, appetite and weight both trending back upward once treatment stops. The exact percentage differs somewhat between studies and compounds, but the underlying mechanism, a hormone-mimicking effect that fades once the medication clears, is shared across semaglutide, tirzepatide, and the rest of the GLP-1 class, whether the specific product is Ozempic, Wegovy, Zepbound, or Mounjaro.

The appetite suppression fading is not the medication failing. It is the medication leaving your system, exactly as expected.

Three things that change how much comes back

  • A protein floor that does not depend on the drug. Protein was likely doing some of the fullness work alongside the medication the whole time. Keeping it consistent after stopping removes one less thing that has to be rebuilt from scratch.
  • Strength training that protects the muscle you already have. Muscle is what keeps your metabolism from dropping as fast as the number on the scale, which matters more, not less, once appetite starts working against you again.
  • Watching your weight as a trend, not a single number. A trend line catches the early slope of a regain within a few weeks, while a single weigh-in a month later only shows you the damage after it has already built up.

None of these three require staying on the medication or replacing it with anything. They are the parts of the outcome that were always somewhat separate from the drug itself, even while you were taking it, which is exactly why they carry more weight once appetite suppression is no longer doing part of the job for you.

When to loop in your prescriber

Anything about your treatment itself, whether stopping is the right call for you, what your options are, or how you are feeling on or off the medication, is a conversation for your prescriber, not something to work out from a blog post. What you can manage on your own is everything downstream of that decision: what you eat, how you move, and how closely you watch the trend once appetite starts shifting back.

How OffRamp helps

OffRamp's Regain Radar turns your weigh-ins into a rolling trend, so the early slope of a rebound shows up in weeks rather than getting discovered months later. Paired with a daily protein floor and short built-in strength sessions, it gives you the same three levers that mattered most in the trial data, the parts of the outcome that were never actually about the medication in the first place.